Skip to main content Back to Top
Advertisement

5/26/2023

Carboplatin Solution for Injection

Products Affected - Description

    • Carboplatin solution for injection, Accord, 10 mg/mL, 15 mL multiple dose vial, 1 count, NDC 16729-0295-33
    • Carboplatin solution for injection, Accord, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 16729-0295-34
    • Carboplatin solution for injection, Accord, 10 mg/mL, 5 mL multiple dose vial, 1 count, NDC 16729-0295-31
    • Carboplatin solution for injection, Accord, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 16729-0295-12
    • Carboplatin solution for injection, Eugia US, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 55150-0335-01
    • Carboplatin solution for injection, Eugia US, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 55150-0386-01
    • Carboplatin solution for injection, Fresenius Kabi, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 63323-0172-60
    • Carboplatin solution for injection, Pfizer, 10 mg/mL, 15 mL multiple dose vial, 1 count, NDC 61703-0339-22
    • Carboplatin solution for injection, Pfizer, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 61703-0339-50
    • Carboplatin solution for injection, Pfizer, 10 mg/mL, 5 mL multiple dose vial, 1 count, NDC 61703-0339-18
    • Carboplatin solution for injection, Pfizer, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 61703-0339-56
    • Carboplatin solution for injection, Teva, 10 mg/mL, 45 mL multiple dose vial, 1 count, NDC 00703-4248-01
    • Carboplatin solution for injection, Teva, 10 mg/mL, 5 mL multiple dose vial, 1 count, NDC 00703-4244-01
    • Carboplatin solution for injection, Teva, 10 mg/mL, 60 mL multiple dose vial, 1 count, NDC 00703-4239-01

Reason for the Shortage

    • Accord has carboplatin on shortage due to manufacturing delays.
    • Eugia has carboplatin on shortage due to increased demand.
    • Fresenius Kabi has carboplatin on shortage due to increased demand.
    • Pfizer has carboplatin on shortage due to increased demand.
    • Teva did not provide a reason for the shortage.

Available Products

    • Carboplatin solution for injection, Teva, 10 mg/mL, 15 mL multiple dose vial, 1 count, NDC 00703-4246-01

Estimated Resupply Dates

    • Accord has 10 mg/mL 5 mL and 15 mL vials on back order and the company cannot estimate a release date. The 45 mL and 60 mL vials are on intermittent back order and small quantities are being released as they become available. These are available through wholesalers and drop shipments. Orders can be requested via customer service at: [email protected]
    • Eugia has carboplatin 10 mg/mL 45 mL and 60 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Fresenius Kabi has carboplatin 10 mg/mL 60 mL vials on back order and the company estimates a release date of early-June 2023.
    • Pfizer has carboplatin 10 mg/mL 45 mL and 60 mL vials available in limited supply. The 5 mL and 15 mL vials are on back order and the company estimates a release date of July 2023 for the 5 mL vials and September 2023 for the 15 mL vials.
    • Teva has carboplatin 10 mg/mL 5 mL, 45 mL, and 60 mL vials on back order and the company estimates a release date of May 2023.

Implications for Patient Care

Updated

Updated May 26, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 28, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.